Neoplasms

Blood and Lymph Conditions

All Conditions

Leukemia

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Anti-Infective Agents

Vitamins

Amino Acids

Gemcitabine

Paclitaxel

Carboplatin

Pemetrexed

Docetaxel

Everolimus

Albumin-Bound Paclitaxel

Trametinib

Erlotinib Hydrochloride

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Immunosuppressive Agents

Immunologic Factors

Tyrosine Kinase Inhibitors

Folinic Acid

Folate

Vitamin B9

Tyrosine

Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.

Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.

GSK1120212

dose as defined in the dose escalation protocol.

Docetaxel + GSK1120212

Erlotinib + GSK1120212

dose as defined in the dose escalation protocol

Pemetrexed + GSK1120212

Carboplatin + GSK1120212

Nab-paclitaxel + GSK1120212

Gemcitabine + GSK1120212

Everolimus + GSK1120212

Novartis Pharmaceuticals

This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.

GSK1120212 Rollover Study

MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors or Leukemia

Number of participants with adverse events as a measure of safety and tolerability

Subjects on GSK1120212 Monotherapy and have been treated less than 24 weeks in their parent study.

Cohort A (GSK1120212 < 24 Weeks)

Cohort B (GSK1120212 >= 24 Weeks)

Total

Age, Continuous

Sex: Female, Male

Race/Ethnicity, Customized

Study Director

Adverse Events

Treatment-Related Adverse Events

Serious Adverse Events

Treatment-Related Serious Adverse Events

Number of Participants With Adverse Events

Overall Study

Spots Global Cancer Trial Database for erlotinib + gsk1120212